Cargando…

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

BRCA1 mutant carcinomas are sensitive to PARP inhibitor (PARPi) therapy; however, resistance arises. BRCA1 BRCT domain mutant proteins do not fold correctly and are subject to proteasomal degradation, resulting in PARPi sensitivity. In this study, we show that cell lines and patient-derived tumors,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yifan, Bernhardy, Andrea J., Nacson, Joseph, Krais, John J., Tan, Yin-Fei, Nicolas, Emmanuelle, Radke, Marc R., Handorf, Elizabeth, Llop-Guevara, Alba, Balmaña, Judith, Swisher, Elizabeth M., Serra, Violeta, Peri, Suraj, Johnson, Neil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906494/ https://www.ncbi.nlm.nih.gov/pubmed/31827092 http://dx.doi.org/10.1038/s41467-019-13530-6

Ejemplares similares

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance
por: Nacson, Joseph, et al.
Publicado: (2018)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
por: Aziz, Diar, et al.
Publicado: (2021)

RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage
por: Krais, John J., et al.
Publicado: (2021)

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
por: Nesic, Ksenija, et al.
Publicado: (2023)

Predicting human genes susceptible to genomic instability associated with Alu/Alu-mediated rearrangements
por: Song, Xiaofei, et al.
Publicado: (2018)

Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities
por: Krais, John J., et al.
Publicado: (2023)

Clinical consequences of BRCA2 hypomorphism
por: Castells-Roca, Laia, et al.
Publicado: (2021)

An Alu-derived intronic splicing enhancer facilitates intronic processing and modulates aberrant splicing in ATM
por: Pastor, Tibor, et al.
Publicado: (2009)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
por: Kondrashova, Olga, et al.
Publicado: (2018)

Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition
por: Cruz, Olga Villamar, et al.
Publicado: (2016)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
por: Castroviejo‐Bermejo, Marta, et al.
Publicado: (2018)

Easy and fast PCR‐based protocol allows characterization of breakpoints resulting from Alu/Alu‐mediated genomic rearrangements
por: Majer, Filip, et al.
Publicado: (2021)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation
por: Cedrés, Susana, et al.
Publicado: (2018)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Alu-element insertion in an OPA1 intron sequence associated with autosomal dominant optic atrophy
por: Gallus, Gian Nicola, et al.
Publicado: (2010)

Sam68 binds Alu-rich introns in SMN and promotes pre-mRNA circularization
por: Pagliarini, Vittoria, et al.
Publicado: (2020)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
por: Sullivan-Reed, Katherine, et al.
Publicado: (2018)

The Identification of Large Rearrangements Involving Intron 2 of the CDH1 Gene in BRCA1/2 Negative and Breast Cancer Susceptibility
por: Ben Aissa-Haj, Jihenne, et al.
Publicado: (2022)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
por: Cruz, C, et al.
Publicado: (2018)

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers
por: Shah, Jennifer B., et al.
Publicado: (2022)

An Intronic Alu Element Attenuates the Transcription of a Long Non-coding RNA in Human Cell Lines
por: Pérez-Molina, Rosario, et al.
Publicado: (2020)

Insertion of an Alu‐like element in MLH1 intron 7 as a novel cause of Lynch syndrome
por: Li, Yirong, et al.
Publicado: (2020)

Clinical significance of large rearrangements in BRCA1 and BRCA2
por: Judkins, Thaddeus, et al.
Publicado: (2012)

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
por: Csizmar, Clifford M., et al.
Publicado: (2021)

A Genomewide Screen for Suppressors of Alu-Mediated Rearrangements Reveals a Role for PIF1
por: Chisholm, Karen M., et al.
Publicado: (2012)

PopAlu: population-scale detection of Alu polymorphisms
por: Qian, Yu, et al.
Publicado: (2015)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

A decade of clinical development of PARP inhibitors in perspective
por: Mateo, J, et al.
Publicado: (2019)

Genomic rearrangements in BRCA1 and BRCA2: A literature review
por: Ewald, Ingrid Petroni, et al.
Publicado: (2009)

Alu RNP and Alu RNA regulate translation initiation in vitro
por: Häsler, Julien, et al.
Publicado: (2006)

Alu and B1 Repeats Have Been Selectively Retained in the Upstream and Intronic Regions of Genes of Specific Functional Classes
por: Tsirigos, Aristotelis, et al.
Publicado: (2009)

Human intron-encoded AluACA RNAs and telomerase RNA share a common element promoting RNA accumulation
por: Ketele, Amandine, et al.
Publicado: (2016)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Brca1 mutations in the coiled-coil domain impede Rad51 loading on DNA and mouse development
por: Krais, J. J., et al.
Publicado: (2020)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Contribution of Large Genomic Rearrangements in Italian Lynch Syndrome Patients: Characterization of a Novel Alu-Mediated Deletion
por: Duraturo, Francesca, et al.
Publicado: (2013)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy
por: Cruz, Cristina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2fvkpcjf7ttbntemcvl7oadvaq